Cancer management during the COVID-19 world pandemic.
COVID-19 outbreak
Cancer management
Immune system
Infection
SARS-CoV-2
Therapy
mRNA vaccines
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
09
06
2023
accepted:
10
08
2023
medline:
27
11
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Since 2019, the world has been experiencing an outbreak of a novel beta-coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2. The worldwide spread of this virus has been a severe challenge for public health, and the World Health Organization declared the outbreak a public health emergency of international concern. As of June 8, 2023, the virus' rapid spread had caused over 767 million infections and more than 6.94 million deaths worldwide. Unlike previous SARS-CoV-1 and Middle East respiratory syndrome coronavirus outbreaks, the COVID-19 outbreak has led to a high death rate in infected patients; this has been caused by multiorgan failure, which might be due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors-functional receptors of SARS-CoV-2-in multiple organs. Patients with cancer may be particularly susceptible to COVID-19 because cancer treatments (e.g., chemotherapy, immunotherapy) suppress the immune system. Thus, patients with cancer and COVID-19 may have a poor prognosis. Knowing how to manage the treatment of patients with cancer who may be infected with SARS-CoV-2 is essential. Treatment decisions must be made on a case-by-case basis, and patient stratification is necessary during COVID-19 outbreaks. Here, we review the management of COVID-19 in patients with cancer and focus on the measures that should be adopted for these patients on the basis of the organs or tissues affected by cancer and by the tumor stage.
Identifiants
pubmed: 37642709
doi: 10.1007/s00262-023-03524-1
pii: 10.1007/s00262-023-03524-1
doi:
Substances chimiques
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3427-3444Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B (2022) COVID-19 in cancer patients. Trans R Soc Trop Med Hyg. https://doi.org/10.1093/trstmh/trac015
doi: 10.1093/trstmh/trac015
pubmed: 35483750
Kamboj M, Sepkowitz KA (2009) Nosocomial infections in patients with cancer. Lancet Oncol 10:589–597. https://doi.org/10.1016/S1470-2045(09)70069-5
doi: 10.1016/S1470-2045(09)70069-5
pubmed: 19482247
Li J-Y, Duan X-F, Wang L-P, Xu Y-J, Huang L, Zhang T-F et al (2014) Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. https://doi.org/10.1155/2014/286170
doi: 10.1155/2014/286170
pubmed: 25254224
pmcid: 4352485
Longbottom ER, Torrance HDT, Owen HC, Fragkou PC, Hinds CJ, Pearse RM et al (2016) Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg 264:370–377. https://doi.org/10.1097/SLA.0000000000001484
doi: 10.1097/SLA.0000000000001484
pubmed: 26445474
Sica A, Massarotti M (2017) Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 85:117–125. https://doi.org/10.1016/j.jaut.2017.07.010
doi: 10.1016/j.jaut.2017.07.010
pubmed: 28728794
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M et al (2020) A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an International Collaborative Group. Oncologist 25:e936–e945. https://doi.org/10.1634/theoncologist.2020-0213
doi: 10.1634/theoncologist.2020-0213
pubmed: 32243668
pmcid: 7288661
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Lond Engl 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
doi: 10.1016/S0140-6736(20)30211-7
Cron RQ, Chatham WW (2020) The rheumatologist’s role in COVID-19. J Rheumatol 47:639–642. https://doi.org/10.3899/jrheum.200334
doi: 10.3899/jrheum.200334
pubmed: 32209661
Fajgenbaum DC, June CH (2020) Cytokine storm. N Engl J Med 383:2255–2273. https://doi.org/10.1056/NEJMra2026131
doi: 10.1056/NEJMra2026131
pubmed: 33264547
pmcid: 7727315
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55:105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
doi: 10.1016/j.ijantimicag.2020.105924
pubmed: 32081636
pmcid: 7127800
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M et al (2020) Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584:463–469. https://doi.org/10.1038/s41586-020-2588-y
doi: 10.1038/s41586-020-2588-y
pubmed: 32717743
pmcid: 7477538
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
doi: 10.1016/S0140-6736(20)30183-5
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R (2020) The COVID-19 cytokine storm; what we know so far. Front Immunol 11:1446. https://doi.org/10.3389/fimmu.2020.01446
doi: 10.3389/fimmu.2020.01446
pubmed: 32612617
pmcid: 7308649
Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:846–848. https://doi.org/10.1007/s00134-020-05991-x
doi: 10.1007/s00134-020-05991-x
pubmed: 32125452
pmcid: 7080116
Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K et al (2021) Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 27:1752–1760. https://doi.org/10.1038/s41591-021-01499-z
doi: 10.1038/s41591-021-01499-z
pubmed: 34480127
pmcid: 8516650
Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T et al (2021) Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA 326:230–239. https://doi.org/10.1001/jama.2021.9508
doi: 10.1001/jama.2021.9508
pubmed: 34283183
pmcid: 8293025
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD et al (2021) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 384:20–30. https://doi.org/10.1056/NEJMoa2030340
doi: 10.1056/NEJMoa2030340
pubmed: 33332779
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT et al (2021) Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326:499–518. https://doi.org/10.1001/jama.2021.11330
doi: 10.1001/jama.2021.11330
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7
doi: 10.1038/s41586-020-2012-7
pubmed: 32015507
pmcid: 7095418
Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J et al (2020) Two things about COVID-19 might need attention. https://doi.org/10.20944/preprints202002.0315.v1
Peng L, Zagorac S, Stebbing J (1990) Managing patients with cancer in the COVID-19 era. Eur J Cancer Oxf Engl 2020(132):5–7. https://doi.org/10.1016/j.ejca.2020.03.028
doi: 10.1016/j.ejca.2020.03.028
Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:335–337. https://doi.org/10.1016/S1470-2045(20)30096-6
doi: 10.1016/S1470-2045(20)30096-6
pubmed: 32066541
pmcid: 7159000
Stockman LJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3:e343. https://doi.org/10.1371/journal.pmed.0030343
doi: 10.1371/journal.pmed.0030343
pubmed: 16968120
pmcid: 1564166
Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA et al (2018) Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197:757–767. https://doi.org/10.1164/rccm.201706-1172OC
doi: 10.1164/rccm.201706-1172OC
pubmed: 29161116
Shang L, Zhao J, Hu Y, Du R, Cao B (2020) On the use of corticosteroids for 2019-nCoV pneumonia. Lancet Lond Engl 395:683–684. https://doi.org/10.1016/S0140-6736(20)30361-5
doi: 10.1016/S0140-6736(20)30361-5
Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet Lond Engl 395:473–475. https://doi.org/10.1016/S0140-6736(20)30317-2
doi: 10.1016/S0140-6736(20)30317-2
Xu X, Han M, Li T, Sun W, Wang D, Fu B et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 117:10970–10975. https://doi.org/10.1073/pnas.2005615117
doi: 10.1073/pnas.2005615117
pubmed: 32350134
pmcid: 7245089
Dyck L, Mills KHG (2017) Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 47:765–779. https://doi.org/10.1002/eji.201646875
doi: 10.1002/eji.201646875
pubmed: 28393361
Cron RQ, Caricchio R, Chatham WW (2021) Calming the cytokine storm in COVID-19. Nat Med 27:1674–1675. https://doi.org/10.1038/s41591-021-01500-9
doi: 10.1038/s41591-021-01500-9
pubmed: 34480126
Richards M, Anderson M, Carter P, Ebert BL, Mossialos E (2020) The impact of the COVID-19 pandemic on cancer care. Nat Cancer 1:565–567. https://doi.org/10.1038/s43018-020-0074-y
doi: 10.1038/s43018-020-0074-y
pubmed: 35121972
pmcid: 7238956
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet Lond Engl 395:1907–1918. https://doi.org/10.1016/S0140-6736(20)31187-9
doi: 10.1016/S0140-6736(20)31187-9
Elrobaa IH, New KJ (2021) COVID-19: pulmonary and extra pulmonary manifestations. Front Public Health 9:711616. https://doi.org/10.3389/fpubh.2021.711616
doi: 10.3389/fpubh.2021.711616
pubmed: 34650947
pmcid: 8505777
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol Off J Eur Soc Med Oncol 31:894–901. https://doi.org/10.1016/j.annonc.2020.03.296
doi: 10.1016/j.annonc.2020.03.296
Jindal V, Sahu KK, Gaikazian S, Siddiqui AD, Jaiyesimi I (2020) Cancer treatment during COVID-19 pandemic. Med Oncol Northwood Lond Engl 37:58. https://doi.org/10.1007/s12032-020-01382-w
doi: 10.1007/s12032-020-01382-w
Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA et al (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet. https://doi.org/10.1016/S0140-6736(20)31173-9
doi: 10.1016/S0140-6736(20)31173-9
pubmed: 33341152
Hanna TP, Evans GA, Booth CM (2020) Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 17:268–270. https://doi.org/10.1038/s41571-020-0362-6
doi: 10.1038/s41571-020-0362-6
pubmed: 32242095
pmcid: 7117554
Raphael MJ, Biagi JJ, Kong W, Mates M, Booth CM, Mackillop WJ (2016) The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 160:17–28. https://doi.org/10.1007/s10549-016-3960-3
doi: 10.1007/s10549-016-3960-3
pubmed: 27632288
Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L et al (1990) Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer Oxf Engl 2015(51):1874–1881. https://doi.org/10.1016/j.ejca.2015.07.003
doi: 10.1016/j.ejca.2015.07.003
Tang A, Neeman E, Vuong B, Arasu VA, Liu R, Kuehner GE et al (2022) Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system. Breast Cancer Res Treat 191:665–675. https://doi.org/10.1007/s10549-021-06468-1
doi: 10.1007/s10549-021-06468-1
pubmed: 34988767
pmcid: 8731186
Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G et al (2020) Management of cancer surgery cases during the covid-19 pandemic: considerations. Ann Surg Oncol 27:1717–1720. https://doi.org/10.1245/s10434-020-08461-2
doi: 10.1245/s10434-020-08461-2
pubmed: 32270420
pmcid: 7141488
Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ et al (2020) Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 181:487–497. https://doi.org/10.1007/s10549-020-05644-z
doi: 10.1007/s10549-020-05644-z
pubmed: 32333293
pmcid: 7181102
Di Lena É, Hopkins B, Wong SM, Meterissian S (2022) Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: a multi-institutional matched historical cohort study. Surgery 171:666–672. https://doi.org/10.1016/j.surg.2021.10.033
doi: 10.1016/j.surg.2021.10.033
pubmed: 34862071
Papautsky EL, Hamlish T (2020) Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat 184:249–254. https://doi.org/10.1007/s10549-020-05828-7
doi: 10.1007/s10549-020-05828-7
pubmed: 32772225
pmcid: 7415197
Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M et al (2017) Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol 34:119. https://doi.org/10.1007/s12032-017-0975-5
doi: 10.1007/s12032-017-0975-5
pubmed: 28526922
Sobhani N, D’Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP et al (2019) Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer. Cells 8:E321. https://doi.org/10.3390/cells8040321
doi: 10.3390/cells8040321
Sobhani N, Fassl A, Mondani G, Generali D, Otto T (2021) Targeting aberrant FGFR signaling to overcome CDK4/6 inhibitor resistance in breast cancer. Cells 10:293. https://doi.org/10.3390/cells10020293
doi: 10.3390/cells10020293
pubmed: 33535617
pmcid: 7912842
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B et al (2021) COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Ther Adv Med Oncol 13:17588359211053416. https://doi.org/10.1177/17588359211053416
doi: 10.1177/17588359211053416
pubmed: 34777582
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primer 6:92. https://doi.org/10.1038/s41572-020-00224-3
doi: 10.1038/s41572-020-00224-3
Jensen K, Dalby RB, Bouchelouche K, Pedersen EM, Kalmar S (2022) Telehealth in multidisciplinary target delineation for radiotherapy during the COVID-19 pandemic. A review and a case. Semin Nucl Med 52:79–85. https://doi.org/10.1053/j.semnuclmed.2021.06.002
doi: 10.1053/j.semnuclmed.2021.06.002
pubmed: 34217435
Vasiliadou I, Noble D, Hartley A, Moleron R, Sanghera P, Urbano TG et al (2021) A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemic. Clin Transl Radiat Oncol 30:50–59. https://doi.org/10.1016/j.ctro.2021.06.002
doi: 10.1016/j.ctro.2021.06.002
pubmed: 34226880
pmcid: 8242198
Subramaniyan V, Fuloria S, Gupta G, Kumar DH, Sekar M, Sathasivam KV et al (2022) A review on epidermal growth factor receptor’s role in breast and non-small cell lung cancer. Chem Biol Interact 351:109735. https://doi.org/10.1016/j.cbi.2021.109735
doi: 10.1016/j.cbi.2021.109735
pubmed: 34742684
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E et al (2020) Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 371:4087. https://doi.org/10.1136/bmj.m4087
doi: 10.1136/bmj.m4087
Fujita K, Ito T, Saito Z, Kanai O, Nakatani K, Mio T (2020) Impact of COVID-19 pandemic on lung cancer treatment scheduling. Thorac Cancer 11:2983–2986. https://doi.org/10.1111/1759-7714.13615
doi: 10.1111/1759-7714.13615
pubmed: 32790028
pmcid: 7436133
Sha Z, Chang K, Mi J, Liang Z, Hu L, Long F et al (2020) The impact of the COVID-19 pandemic on lung cancer patients. Ann Palliat Med 9:3373–3378. https://doi.org/10.21037/apm-20-1662
doi: 10.21037/apm-20-1662
pubmed: 33065788
Institute of Medicine (US) Committee on Quality of Health Care in America (2001) Crossing the quality chasm: a new health system for the 21st century. National Academies Press (US), Washington (DC)
Madan A, Siglin J, Khan A (2020) Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med 9:9205–9218. https://doi.org/10.1002/cam4.3534
doi: 10.1002/cam4.3534
pubmed: 33078903
pmcid: 7774721
Gosain R, Abdou Y, Singh A, Rana N, Puzanov I, Ernstoff MS (2020) COVID-19 and cancer: a comprehensive review. Curr Oncol Rep 22:53. https://doi.org/10.1007/s11912-020-00934-7
doi: 10.1007/s11912-020-00934-7
pubmed: 32385672
pmcid: 7206576
Farah E, Ali R, Tope P, El-Zein M, Franco EL (2021) McGill task force on Covid-and cancer null a review of canadian cancer-related clinical practice guidelines and resources during the COVID-19 pandemic. Curr Oncol 28:1020–1033. https://doi.org/10.3390/curroncol28020100
doi: 10.3390/curroncol28020100
pubmed: 33669102
Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England n.d. https://www.urotoday.com/recent-abstracts/covid-19-and-genitourinary-cancers/121299-interim-treatment-change-options-during-the-covid-19-pandemic-endorsed-by-nhs-england.html . Accessed 29 Oct 2022
Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N et al (2020) Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol Off J Eur Soc Med Oncol 31:1320–1335. https://doi.org/10.1016/j.annonc.2020.07.010
doi: 10.1016/j.annonc.2020.07.010
Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC et al (2020) Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer 8:e000878. https://doi.org/10.1136/jitc-2020-000878
doi: 10.1136/jitc-2020-000878
pubmed: 32300051
pmcid: 7204613
Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC (2020) Outcomes of COVID-19 patients under cytotoxic cancer chemotherapy in Brazil. Cancers 12:E3490. https://doi.org/10.3390/cancers12123490
doi: 10.3390/cancers12123490
Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, Narendra V et al (2020) Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 38:3538–3546. https://doi.org/10.1200/JCO.20.01307
doi: 10.1200/JCO.20.01307
Di Felice G, Visci G, Teglia F, Angelini M, Boffetta P (2022) Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients. Elife 11:e74634. https://doi.org/10.7554/eLife.74634
doi: 10.7554/eLife.74634
pubmed: 35171096
pmcid: 8956284
Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E et al (2021) Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol 22:1669–1680. https://doi.org/10.1016/S1470-2045(21)00573-8
doi: 10.1016/S1470-2045(21)00573-8
pubmed: 34741822
pmcid: 8565932
Al-Quteimat OM, Amer AM (2020) The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol 43:452–455. https://doi.org/10.1097/COC.0000000000000712
doi: 10.1097/COC.0000000000000712
pubmed: 32304435
Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI (2020) A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med 172:756–758. https://doi.org/10.7326/M20-1133
doi: 10.7326/M20-1133
pubmed: 32219410
Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD (2020) Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov 10:1121–1128. https://doi.org/10.1158/2159-8290.CD-20-0596
doi: 10.1158/2159-8290.CD-20-0596
pubmed: 32398243
pmcid: 7416461
Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J et al (1990) Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer Oxf Engl 2020(133):120–130. https://doi.org/10.1016/j.ejca.2020.04.010
doi: 10.1016/j.ejca.2020.04.010
Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V et al (2020) Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. Br J Haematol 190:e279–e282. https://doi.org/10.1111/bjh.16935
doi: 10.1111/bjh.16935
pubmed: 32526039
pmcid: 7307054
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M et al (2020) Hematological findings and complications of COVID-19. Am J Hematol 95:834–847. https://doi.org/10.1002/ajh.25829
doi: 10.1002/ajh.25829
pubmed: 32282949
pmcid: 7262337
Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nuñez N, Simonis A et al (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34:2688–2703. https://doi.org/10.1038/s41375-020-0818-9
doi: 10.1038/s41375-020-0818-9
pubmed: 32358567
Singh Y, Fuloria NK, Fuloria S, Subramaniyan V, Almalki WH, Gupta G et al (2021) Disruption of the biological activity of protease-activated receptors2/4 in adults rather than children in SARS CoV-2 virus-mediated mortality in COVID-19 infection. Drug Dev Res 82:1075–1078. https://doi.org/10.1002/ddr.21874
doi: 10.1002/ddr.21874
pubmed: 34469011
pmcid: 8653207
Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U et al (2021) Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother Cancer 9:e002277. https://doi.org/10.1136/jitc-2020-002277
doi: 10.1136/jitc-2020-002277
pubmed: 33753569
Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu C-Y, Shyr Y et al (2021) Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open 4:e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330
doi: 10.1001/jamanetworkopen.2021.34330
pubmed: 34767021
pmcid: 8590166
Leonetti A, Facchinetti F, Zielli T, Brianti E, Tiseo M (1990) COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors. Eur J Cancer Oxf Engl 2020(132):122–124. https://doi.org/10.1016/j.ejca.2020.04.004
doi: 10.1016/j.ejca.2020.04.004
De Simone B, Chouillard E, Sartelli M, Biffl WL, Di Saverio S, Moore EE et al (2021) The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper. World J Emerg Surg WJES 16:14. https://doi.org/10.1186/s13017-021-00349-0
doi: 10.1186/s13017-021-00349-0
pubmed: 33752721
Iqbal MR, Subramonian S, Matwala K, Morrison C, Karamanakos S, Haque S-U et al (2021) Instituting a green zone for elective surgery during the second wave of COVID-19. Cureus 13:e19584. https://doi.org/10.7759/cureus.19584
doi: 10.7759/cureus.19584
pubmed: 34926055
pmcid: 8672239
COVIDSurg Collaborative (2020) Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet Lond Engl 396:27–38. https://doi.org/10.1016/S0140-6736(20)31182-X
doi: 10.1016/S0140-6736(20)31182-X
Turaga KK, Girotra S (2020) Are we harming cancer patients by delaying their cancer surgery during the COVID-19 pandemic? Ann Surg. https://doi.org/10.1097/SLA.0000000000003967
doi: 10.1097/SLA.0000000000003967
pubmed: 32487802
Al-Quteimat OM, Amer AM (2020) The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. https://doi.org/10.1097/COC.0000000000000712
doi: 10.1097/COC.0000000000000712
pubmed: 32304435
pmcid: 7188063
Mohanty A, Agnihotri S, Mehta A, Rawal S (2021) COVID-19 and cancer: sailing through the tides. Pathol Res Pract 221:153417. https://doi.org/10.1016/j.prp.2021.153417
doi: 10.1016/j.prp.2021.153417
pubmed: 33857716
pmcid: 7997300
Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR et al (2020) ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood 135:1829–1832. https://doi.org/10.1182/blood.2020006028
doi: 10.1182/blood.2020006028
pubmed: 32275740
Yao J-J, Jin Y-N, Wang S-Y, Zhang F, Zhou G-Q, Zhang W-J et al (2018) The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer 18:740. https://doi.org/10.1186/s12885-018-4495-2
doi: 10.1186/s12885-018-4495-2
pubmed: 30012115
pmcid: 6048841
Aghili M, Ghalehtaki R, Mousavi Darzikolaee N, Jafari F, Moshtaghian M (2020) Radiotherapy and COVID-19: practical recommendations from Iran. Radiother Oncol 149:70–71. https://doi.org/10.1016/j.radonc.2020.04.051
doi: 10.1016/j.radonc.2020.04.051
pubmed: 32387545
pmcid: 7204685
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML et al (2022) mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185:457-466.e4. https://doi.org/10.1016/j.cell.2021.12.033
doi: 10.1016/j.cell.2021.12.033
pubmed: 34995482
pmcid: 8733787
Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M et al (2020) Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 4:1059–1071. https://doi.org/10.1200/CCI.20.00134
doi: 10.1200/CCI.20.00134
pubmed: 33253013
Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED et al (2020) Impact of the COVID-19 pandemic on cancer care: a global collaborative study. JCO Glob Oncol 6:1428–1438. https://doi.org/10.1200/GO.20.00351
doi: 10.1200/GO.20.00351
pubmed: 32986516
Englum BR, Prasad NK, Lake RE, Mayorga-Carlin M, Turner DJ, Siddiqui T et al (2022) Impact of the COVID-19 pandemic on diagnosis of new cancers: a national multicenter study of the Veterans Affairs Healthcare System. Cancer 128:1048–1056. https://doi.org/10.1002/cncr.34011
doi: 10.1002/cncr.34011
pubmed: 34866184
Broom A, Kenny K, Page A, Cort N, Lipp ES, Tan AC et al (2020) The paradoxical effects of COVID-19 on cancer care: current context and potential lasting impacts. Clin Cancer Res Off J Am Assoc Cancer Res 26:5809–5813. https://doi.org/10.1158/1078-0432.CCR-20-2989
doi: 10.1158/1078-0432.CCR-20-2989
Dave RV, Kim B, Courtney A, O’Connell R, Rattay T, Taxiarchi VP et al (2021) Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK “Alert Level 4” phase of the B-MaP-C study. Br J Cancer 124:1785–1794. https://doi.org/10.1038/s41416-020-01234-4
doi: 10.1038/s41416-020-01234-4
pubmed: 33767422
pmcid: 7993073
Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J (2020) The impact of COVID-19 on cancer screening: challenges and opportunities. JMIR Cancer 6:e21697. https://doi.org/10.2196/21697
doi: 10.2196/21697
pubmed: 33027039
pmcid: 7599065
Duffy SW, Seedat F, Kearins O, Press M, Walton J, Myles J et al (2022) The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation. Br J Cancer 126:1355–1361. https://doi.org/10.1038/s41416-022-01714-9
doi: 10.1038/s41416-022-01714-9
pubmed: 35110696
pmcid: 8808468
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al (2020) Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 71:2027–2034. https://doi.org/10.1093/cid/ciaa344
doi: 10.1093/cid/ciaa344
pubmed: 32221519
Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B (2022) Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA 327:583–584. https://doi.org/10.1001/jama.2021.24868
doi: 10.1001/jama.2021.24868
pubmed: 34967859
Desai A, Mohammed TJ, Duma N, Garassino MC, Hicks LK, Kuderer NM et al (2021) COVID-19 and cancer: a review of the registry-based pandemic response. JAMA Oncol 7:1882–1890. https://doi.org/10.1001/jamaoncol.2021.4083
doi: 10.1001/jamaoncol.2021.4083
pubmed: 34473192
pmcid: 8805603
Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Tuttle KS et al (2022) SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375:760–764. https://doi.org/10.1126/science.abn7760
doi: 10.1126/science.abn7760
pubmed: 35050643
pmcid: 9799367
Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL et al (2022) mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep Med 3:100529. https://doi.org/10.1016/j.xcrm.2022.100529
doi: 10.1016/j.xcrm.2022.100529
pubmed: 35233550
pmcid: 8784612
Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R et al (2022) Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol 23:865–875. https://doi.org/10.1016/S1470-2045(22)00273-X
doi: 10.1016/S1470-2045(22)00273-X
pubmed: 35660139
pmcid: 9162476
Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans A-MC et al (2021) mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol 22:1681–1691. https://doi.org/10.1016/S1470-2045(21)00574-X
doi: 10.1016/S1470-2045(21)00574-X
pubmed: 34767759
pmcid: 8577843
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet Lond Engl 398:2258–2276. https://doi.org/10.1016/S0140-6736(21)02717-3
doi: 10.1016/S0140-6736(21)02717-3
Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O et al (1990) Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. Eur J Cancer Oxf Engl 2022(171):64–74. https://doi.org/10.1016/j.ejca.2022.04.036
doi: 10.1016/j.ejca.2022.04.036
Singhal T (2020) A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 87:281–286. https://doi.org/10.1007/s12098-020-03263-6
doi: 10.1007/s12098-020-03263-6
pubmed: 32166607
pmcid: 7090728
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM n.d. https://doi.org/10.1056/nejmoa2034577 . Accessed 15 July 2023
Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K et al (2020) Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 21:904–913. https://doi.org/10.1016/S1470-2045(20)30310-7
doi: 10.1016/S1470-2045(20)30310-7
pubmed: 32479787
pmcid: 7259917
Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B et al (2020) Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21:893–903. https://doi.org/10.1016/S1470-2045(20)30309-0
doi: 10.1016/S1470-2045(20)30309-0
pubmed: 32479790
pmcid: 7259911
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C et al (2020) COVID-19 in patients with lung cancer. Ann Oncol Off J Eur Soc Med Oncol 31:1386–1396. https://doi.org/10.1016/j.annonc.2020.06.007
doi: 10.1016/j.annonc.2020.06.007
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M et al (2020) Determinants of COVID-19 disease severity in patients with cancer. Nat Med 26:1218–1223. https://doi.org/10.1038/s41591-020-0979-0
doi: 10.1038/s41591-020-0979-0
pubmed: 32581323
pmcid: 7785283
Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G et al (2020) The immuno-oncological challenge of COVID-19. Nat Cancer 1:946–964. https://doi.org/10.1038/s43018-020-00122-3
doi: 10.1038/s43018-020-00122-3
pubmed: 35121872
Turnquist C, Ryan BM, Horikawa I, Harris BT, Harris CC (2020) Cytokine storms in cancer and COVID-19. Cancer Cell 38:598–601. https://doi.org/10.1016/j.ccell.2020.09.019
doi: 10.1016/j.ccell.2020.09.019
pubmed: 33038939
pmcid: 7531591
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934–943. https://doi.org/10.1001/jamainternmed.2020.0994
doi: 10.1001/jamainternmed.2020.0994
pubmed: 32167524
Vargas AJ, Harris CC (2016) Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 16:525–537. https://doi.org/10.1038/nrc.2016.56
doi: 10.1038/nrc.2016.56
pubmed: 27388699
pmcid: 6662593
Sanguinete MMM, Oliveira PHD, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC et al (2017) Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest 46:677–688. https://doi.org/10.1080/08820139.2017.1360342
doi: 10.1080/08820139.2017.1360342
pubmed: 28872976
Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E et al (2013) p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 123:5247–5257. https://doi.org/10.1172/JCI70355
doi: 10.1172/JCI70355
pubmed: 24231352
pmcid: 3859419
Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:529–539. https://doi.org/10.1007/s00281-017-0629-x
doi: 10.1007/s00281-017-0629-x
pubmed: 28466096
pmcid: 7079893
Cai G, Gao Y, Zeng S, Yu Y, Liu X, Liu D et al (2021) Immunological alternation in COVID-19 patients with cancer and its implications on mortality. Oncoimmunology 10:1854424. https://doi.org/10.1080/2162402X.2020.1854424
doi: 10.1080/2162402X.2020.1854424
pubmed: 33489469
pmcid: 7801126
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ et al (2016) First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 34:4142–4150. https://doi.org/10.1200/JCO.2015.65.3949
doi: 10.1200/JCO.2015.65.3949
Dexamethasone in Hospitalized Patients with Covid-19 | NEJM n.d. https://doi.org/10.1056/nejmoa2021436 . Accessed 15 July 2023
Pasin L, Navalesi P, Zangrillo A, Kuzovlev A, Likhvantsev V, Hajjar LA et al (2021) Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 35:578–584. https://doi.org/10.1053/j.jvca.2020.11.057
doi: 10.1053/j.jvca.2020.11.057
pubmed: 33298370
Michot J-M, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F et al (2020) Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 31:961–964. https://doi.org/10.1016/j.annonc.2020.03.300
doi: 10.1016/j.annonc.2020.03.300
pubmed: 32247642
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N et al (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 20:669–677. https://doi.org/10.1016/S1473-3099(20)30243-7
doi: 10.1016/S1473-3099(20)30243-7
pubmed: 32240634
pmcid: 7158570
Characteristics of COVID-19 patients dying in Italy n.d. https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths . Accessed 15 July 2023
Rischio infettivo da coronavirus COVID 19: indicazioni per l’oncologia. https://www.aiom.it/wp-content/uploads/2020/03/20200313_COVID-19_indicazioni_AIOM-CIPOMO-COMU.pdf . - Google Search n.d. https://www.google.com/search?q=Rischio+infettivo+da+coronavirus+COVID+19%3A+indicazioni+per+l%E2%80%99oncologia.+https%3A%2F%2Fwww.aiom.it%2Fwp-content%2Fuploads%2F2020%2F03%2F20200313_COVID-19_indicazioni_AIOM-CIPOMO-COMU.pdf.&rlz=1C5CHFA_enUS1029US1029&ei=4PWyZIWyEcyoqtsPjI6NQA&ved=0ahUKEwiFopbCu5GAAxVMlGoFHQxHAwgQ4dUDCBA&uact=5&oq=Rischio+infettivo+da+coronavirus+COVID+19%3A+indicazioni+per+l%E2%80%99oncologia.+https%3A%2F%2Fwww.aiom.it%2Fwp-content%2Fuploads%2F2020%2F03%2F20200313_COVID-19_indicazioni_AIOM-CIPOMO-COMU.pdf.&gs_lp=Egxnd3Mtd2l6LXNlcnAirAFSaXNjaGlvIGluZmV0dGl2byBkYSBjb3JvbmF2aXJ1cyBDT1ZJRCAxOTogaW5kaWNhemlvbmkgcGVyIGzigJlvbmNvbG9naWEuIGh0dHBzOi8vd3d3LmFpb20uaXQvd3AtY29udGVudC91cGxvYWRzLzIwMjAvMDMvMjAyMDAzMTNfQ09WSUQtMTlfaW5kaWNhemlvbmlfQUlPTS1DSVBPTU8tQ09NVS5wZGYuSNECUABYAHAAeACQAQCYAQCgAQCqAQC4AQPIAQD4AQHiAwQYACBBiAYB&sclient=gws-wiz-serp . Accessed 15 July 2023
You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R et al (2020) The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol 21:619–621. https://doi.org/10.1016/S1470-2045(20)30204-7
doi: 10.1016/S1470-2045(20)30204-7
pubmed: 32220659
pmcid: 7118635
Overview | COVID-19 rapid guideline: delivery of systemic anticancer treatments | Guidance | NICE 2020. https://www.nice.org.uk/guidance/ng161 . Accessed 15 July 2023
ESMO. Cancer Patient Management During the COVID-19 Pandemic n.d. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic
Healthcare Workers. Cent Dis Control Prev 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html . Accessed 15 July 2023
COVID-19 Patient Care Information. ASCO 2020. https://old-prod.asco.org/covid-resources/patient-care-info . Accessed 15 July 2023
Boutros M, Moujaess E, Kourie HR (2021) Cancer management during the COVID-19 pandemic: choosing between the devil and the deep blue sea. Crit Rev Oncol Hematol 167:103273. https://doi.org/10.1016/j.critrevonc.2021.103273
doi: 10.1016/j.critrevonc.2021.103273
pubmed: 33737160
pmcid: 7959683